Optimizing treatment in homozygous familial hypercholesterolemia: Monocentric observational clinical study on efficacy and safety of evinacumab and lomitapide combination. (PubMed, J Clin Lipidol) - Oct 6, 2026 - "Evinacumab added to lomitapide-based background lipid-lowering therapy was associated with marked reductions in LDL-C, ApoB, and other lipid parameters, with a favorable safety profile. These findings support the potential clinical usefulness of the evinacumab/lomitapide combination in both pediatric and adult patients with HoFH, although decisions regarding lipoprotein apheresis should remain individualized."
Journal • Observational data • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders • Pain • Pediatrics • ANGPTL3 • APOB
|
|
Alberto Zambon; Camilla Portinari; Giorgia Marodin; Lorenzo Previato; Maria Giovanna Lupo; Marta Biolo; Nicola Ferri; Paolo Simioni; Sabina Zambon; Sandra Bertocco
|